Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
84 studies found for:    myeloma AND (women OR woman OR female)
Show Display Options
Rank Status Study
21 Terminated
Has Results
Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant
Condition: Refractory Multiple Myeloma
Interventions: Drug: liposomal doxorubicin;   Drug: bortezomib;   Drug: dexamethasone;   Drug: cyclophosphamide
22 Active, not recruiting S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Conditions: Breast Cancer;   Lung Cancer;   Metastatic Cancer;   Multiple Myeloma;   Plasma Cell Neoplasm;   Prostate Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Procedure: assessment of therapy complications
23 Withdrawn A Phase IIa Study of Sotatercept on Bone Mass and Turnover in Patients With Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Sotatercept;   Drug: Placebo
24 Not yet recruiting Ixazomib, Lenalidomide, Dexamethasone Induction and Extended Consolidation Plus Lenalidomide Maintenance in Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Ixazomib;   Drug: Lenalidomide;   Drug: Dexamethasone
25 Completed
Has Results
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
Condition: Multiple Myeloma
Interventions: Procedure: One Autologous Transplant;   Procedure: Non-Myeloablative Allogeneic Transplant;   Procedure: Second Autologous Transplant;   Drug: Thalidomide;   Drug: Dexamethasone;   Behavioral: Observation
26 Recruiting ACE-011 With Lenalidomide+Dexamethasone for Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: ACE-011;   Drug: Lenalidomide;   Drug: Dexamethasone
27 Active, not recruiting Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma
Conditions: DS Stage I Plasma Cell Myeloma;   DS Stage II Plasma Cell Myeloma;   DS Stage III Plasma Cell Myeloma
Interventions: Drug: Bortezomib;   Drug: Dexamethasone;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide
28 Unknown  Evaluating the Efficacy and Safety of the Lower Dose of Bortezomib Plus Busulfan and Melphalan as a Conditioning Regimen in Patients With Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation- KMM103 Study
Condition: Multiple Myeloma Patients Who Candidate for Autologous Peripheral Blood Stem Cell Transplantation
Intervention: Drug: Bortezomib
29 Active, not recruiting
Has Results
S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Biological: filgrastim;   Biological: sargramostim;   Drug: cyclophosphamide;   Drug: dexamethasone;   Drug: melphalan;   Drug: prednisone;   Drug: thalidomide;   Procedure: peripheral blood stem cell transplantation
30 Recruiting A Study to Collect and Evaluate the Safety and Efficacy Information of Korean Multiple Myeloma Patients Treated With REVLIMID®, After Approval of Marketing Authorization for New Drug in Korea
Condition: Multiple Myeloma
Interventions: Drug: REVLIMID®;   Drug: Dexamethasone
31 Terminated Treatment of Malignant Vertebral Fractures With Percutaneous Balloon Kyphoplasty.
Conditions: Vertebral Fracture;   Multiple Myeloma;   Osteolytic Metastases
Intervention: Device: balloon kyphoplasty
32 Completed
Has Results
American Ginseng in Treating Patients With Fatigue Caused by Cancer
Conditions: Chronic Myeloproliferative Disorders;   Fatigue;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms;   Precancerous Condition;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: American ginseng;   Other: placebo
33 Completed ExAblate (Magnetic Resonance-guided Focused Ultrasound Surgery) Treatment of Metastatic Bone Tumors for the Palliation of Pain
Conditions: Bone Metastases;   Multiple Myeloma
Interventions: Device: ExAblate 2000;   Device: Sham
34 Completed A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With Relapsed Mantle Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, and Related Lymphoid Malignancies
Conditions: Lymphoma, Mantle-cell;   Leukemia, Lymphocytic, Chronic, B-Cell;   Leukemia, Hairy Cell;   Waldenstrom Macroglobulinemia;   Multiple Myeloma
Intervention: Drug: ON01910 Na
35 Active, not recruiting Lenalidomide/Bortezomib/Dexamethasone for Multiple Myeloma (MM)
Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide;   Drug: Bortezomib;   Drug: Dexamethasone
36 Active, not recruiting
Has Results
Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Multiple Myeloma and Renal Disease
Conditions: Relapsed Multiple Myeloma;   End-stage Renal Disease
Intervention: Drug: Carfilzomib
37 Active, not recruiting Cytogenetic Studies in Acute Leukemia and Multiple Myeloma
Conditions: Acute Leukemia;   Acute Lymphoblastic Leukemia;   Myelodysplastic Syndrome;   Multiple Myeloma
Intervention: Genetic: cytogenetic analysis
38 Active, not recruiting
Has Results
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
Conditions: Ovarian Cancer;   Renal Cancer;   Non-small Cell Lung Cancer;   Small Cell Lung Cancer;   Solid Tumors;   Multiple Myeloma;   Lymphoma
Interventions: Drug: Carfilzomib;   Drug: Dexamethasone
39 Recruiting Evaluation of the Safety and the Efficacy of Carfilzomib Combined With Cyclophosphamide and Dexamethasone (CCyd) or Lenalidomide and Dex (CRd) Followed by ASCT or 12 Cycles of Carf Combined With Dex and Len for Patients Eligible for ASCT With Newly Diagnosed Multiple Myeloma.
Condition: MULTIPLE MYELOMA (MM)
Interventions: Drug: Carfilzomib;   Drug: Cyclophosphamide;   Drug: Lenalidomide;   Drug: Dexamethasone
40 Completed Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma
Conditions: Refractory Multiple Myeloma;   Relapsed Multiple Myeloma;   Multiple Myeloma
Interventions: Drug: Bortezomib;   Drug: CC-5013

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years